Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes
- 1 April 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 357 (9262) , 1059-1060
- https://doi.org/10.1016/s0140-6736(00)04306-3
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The role of apoptosis, proliferation, and the Bcl-2–related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDSBlood, 2000
- Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromesBritish Journal of Haematology, 2000
- Expression of the multidrug resistance‐associated protein in myelodysplastic syndromesBritish Journal of Haematology, 2000
- Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)Blood, 1999
- Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatmentLeukemia Research, 1998
- Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromesLeukemia, 1997
- Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cellsBlood, 1996
- Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromesLeukemia Research, 1996
- Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome [letter]Blood, 1996
- Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.Journal of Clinical Oncology, 1993